Nicotinamide adenine dinucleotide (NAD+) occupies a unique position in cellular biochemistry—simultaneously a coenzyme in oxidoreduction reactions (serving as hydride acceptor in glycolysis, TCA cycle, and beta-oxidation) and a substrate for three classes of NAD+-consuming enzymes: sirtuins (SIRT1-7), PARP enzymes (PARP-1 through PARP-16), and CD38/CD157 ectoenzymes. This dual role means NAD+ availability directly couples metabolic flux to epigenetic regulation, DNA repair capacity, and inflammatory signaling. Understanding NAD+ biology requires separate consideration of its biosynthesis, its consumption, and the functional consequences of NAD+ depletion at the enzyme level.
NAD+ Biosynthesis: Three Distinct Pathways
NAD+ is synthesized via three biochemically distinct routes. The de novo pathway (Preiss-Handler/Kynurenine) proceeds from tryptophan through the kynurenine intermediate to quinolinate, which is converted to NAMN (nicotinic acid mononucleotide) by QPRT (quinolinate phosphoribosyl transferase) and then to NAD+ via NMNAT (nicotinamide mononucleotide adenylyl transferase) isoforms 1–3. This pathway predominates in hepatocytes and is suppressed by chronic inflammation (IDO1 diversion of tryptophan) and aging. The Preiss-Handler pathway uses nicotinic acid (NA) from diet → NaMN → NaAD → NAD+ via NAPT and NMNAT. The salvage pathway is the primary NAD+ biosynthetic route in most peripheral tissues, proceeding: nicotinamide (NAM) → NMN via NAMPT (nicotinamide phosphoribosyltransferase, the rate-limiting enzyme) → NAD+ via NMNAT. NAMPT is the critical bottleneck: it is inhibited by high NAM concentrations (product inhibition), regulated by SIRT1 in a feedback loop, and declines substantially with age. In 22-month-old C57BL/6 mice, hepatic NAMPT protein expression is reduced approximately 60% compared to 4-month controls (western blot), correlating with NAD+ depletion in liver, muscle, and brain.
CD38: The Principal NAD+ Consumer During Aging
CD38 (cluster of differentiation 38) is a type II transmembrane glycoprotein with glycohydrolase and ADP-ribosyl cyclase activity, using NAD+ as substrate to produce ADPR (ADP-ribose) and Nam (nicotinamide). While CD38 has roles in calcium signaling (via cADPR), its most critical research implication is as the dominant NAD+ consumer in aging tissues. CD38 expression increases approximately 2–4-fold in mouse liver, adipose, and muscle between 6 and 32 months of age, and this increase inversely correlates with tissue NAD+ levels (Pearson r ≈ −0.85 in published datasets). CD38 is predominantly expressed in immune cells (macrophages, NK cells), and its age-associated increase reflects the sterile inflammatory state of aged tissues. In CD38-knockout mice, NAD+ levels at 32 months remain comparable to 6-month wild-type levels, and metabolic phenotype (including body composition, glucose tolerance, and mitochondrial function) is substantially preserved. Pharmacological CD38 inhibition with 78c (a thiazoloquin(az)olinone CD38 inhibitor) at 20 mg/kg/day restored NAD+ to ~140% of vehicle aged controls in a 2-week treatment paradigm in 20-month-old mice.
SIRT1-7: NAD+-Dependent Deacylation and Enzymatic Diversity
Sirtuins are class III HDACs (histone deacetylases) that require NAD+ as an obligate co-substrate, consuming one NAD+ molecule per deacylation cycle. Their substrates, compartmentalization, and primary biological roles are distinct: SIRT1 (nuclear/cytoplasmic, deacetylates p53, NF-κB, PGC-1α, FOXO1) governs metabolic adaptation and stress responses; SIRT2 (cytoplasmic, deacetylates tubulin, APC/C components) regulates cell cycle and mitosis; SIRT3/4/5 (mitochondrial) control ETC efficiency (SIRT3 on Complex I subunit NDUFA9), fatty acid oxidation, and the urea cycle; SIRT6 (nuclear) removes long-chain fatty acyl groups and regulates telomeric heterochromatin and NF-κB; SIRT7 (nucleolar) deacetylates H3K18Ac and controls rDNA transcription. The Km of SIRT1 for NAD+ is approximately 100–200 µM, meaning that tissue NAD+ concentrations below ~200 µM substantially impair SIRT1 activity—a threshold reached in multiple aged rodent tissues.
Research Formulations: Direct NAD+, NMN, and NR Comparisons
Three primary supplementation approaches for preclinical NAD+ research exist. Direct NAD+ (as sodium or reduced form NADH) faces cell membrane permeability limitations; extracellular NAD+ must be degraded by ectoenzymes (CD38, CD73) to NMN or NAM before cellular uptake, making pharmacokinetics complex. NMN (nicotinamide mononucleotide) is transported into cells via Slc12a8 (a specific NMN transporter identified in murine intestinal cells), with bioavailability well-characterized subcutaneously. NR (nicotinamide riboside) enters cells via equilibrative nucleoside transporters (ENT1/2) and is phosphorylated to NMN intracellularly by NRK1/2. Comparative rodent studies at equimolar doses (500 mg/kg) show NMN and NR both raise tissue NAD+ by 40–90% at peak (2–4h post-administration), with NMN showing faster kinetics and NR showing greater brain penetration in some datasets. All formulations demonstrate lot-to-lot purity variation that requires HPLC >99% verification for reproducible NAD+ quantification endpoints.
- Key readouts: tissue NAD+ by HPLC or enzymatic cycling assay, SIRT1 deacetylase activity, NAMPT western blot, CD38 flow cytometry (immune compartment), NAD+/NADH ratio
- Model considerations: C57BL/6 aged male mice standard for NAD+ decline research; distinguish between tissue compartments (liver NAD+ ≠ muscle NAD+ ≠ brain NAD+)
- Purity standard: HPLC >99%, lot-traceable CoA; NAD+ is hygroscopic and requires desiccated storage to prevent degradation
All compounds discussed in this article are intended for laboratory and research use only. They are not approved for therapeutic, diagnostic, or clinical applications in humans. Investigators must follow institutional protocols for handling controlled research materials.